Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population

The International Journal of Artificial Organs
Fabrizio FabriziPiergiorgio Messa

Abstract

The prevalence and incidence rates of hepatitis B virus (HBV) among patients undergoing maintenance dialysis in developed countries have declined over the last 2 decades thanks to the implementation of numerous infection control procedures in dialysis units, including the hepatitis B vaccine. It is well known that the immune response against HBV vaccine is unsatisfactory in the chronic kidney disease (CKD) population. The seroprotection rate after the HB vaccine schedule is low and the anti-HB titers are reduced, falling logarithmically over time. We did an extensive review of the medical literature on the mechanisms underlying the reduced response rate towards the HBV vaccine in patients with CKD. The efficacy and safety of HBV vaccines for use in the CKD population was also evaluated. Currently available vaccines against HBV are mostly plasma-derived or manufactured by recombinant DNA technology (yielding the S protein of the HBV envelope). The most promising strategy to enhance the immune response toward the HBV vaccine in the dialysis population is given by adjuvanted vaccines. Second-generation recombinant HB vaccines provided with a novel adjuvant (AS04, made of 3-O-4'-desacyl-monophosphoryl lipid A adsorbed on aluminum p...Continue Reading

References

Jan 1, 1992·Nephron·M LombardiP Di Geronimo
Nov 1, 1989·The Journal of Infectious Diseases·W JilgF Deinhardt
Aug 23, 1984·The New England Journal of Medicine·C E StevensW Szmuness
Apr 1, 1994·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A L MarangiC Basile
Jan 25, 2000·American Journal of Nephrology·F Fabrizi, P Martin
Dec 5, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Gerald DaRozaAdeera Levin
Jan 25, 2005·Seminars in Dialysis·Lyn FinelliMatthew J Arduino
Feb 9, 2005·Kidney International·Tejinder S AhujaYong-Fang Kuo
Oct 14, 2005·Kidney International·Norella Kong Chiew TongMichel Stoffel
Jul 16, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jennifer TungChristine H Lee
Jul 21, 2012·Kidney & Blood Pressure Research·Fabrizio FabriziPiergiorgio Messa
Aug 26, 2014·Expert Review of Vaccines·Alicja E Grzegorzewska
Jan 6, 2015·Medical Microbiology and Immunology·Daniel ShouvalMichael Roggendorf

❮ Previous
Next ❯

Citations

May 10, 2018·Seminars in Dialysis·Georges KosmadakisDidier Aguilera
Aug 18, 2020·International Journal of Nephrology and Renovascular Disease·Intissar Haddiya
Aug 12, 2020·Gastroenterología y hepatología·Manuel RodríguezJavier García-Samaniego

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.